Beijing SL Pharmaceutical Co., Ltd. (SHE:002038)

Market Cap	5.58B -17.6%
Revenue (ttm)	591.59M +1.3%
Net Income	-479.28M
EPS	-0.48
Shares Out	1.03B
PE Ratio	n/a
Forward PE	n/a
Dividend	0.01 (0.18%)
Ex-Dividend Date	Jul 4, 2025

Volume	15,356,812
Open	5.49
Previous Close	5.47
Day's Range	5.37 - 5.54
52-Week Range	5.35 - 9.40
Beta	-0.11
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About Beijing SL Pharmaceutical

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People’s Republic of China and internationally. The company’s finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; pegylated human granulocyte-stimulating factor injection; human granulocyte-cell stimulating factor injection; recombinant human basic fibroblast growth factor for external use recombinant human basic fibroblast growth factor gel; human interleukin-11; arsen...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 901
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002038

Financial Performance

In 2025, Beijing SL Pharmaceutical's revenue was 623.64 million, a decrease of -5.57% compared to the previous year's 660.42 million. Losses were -347.20 million, 368.8% more than in 2024.